Iovance Biotherapeutics Investor Relations Material

Iovance Biotherapeutics Inc is a biotechnology company focused on developing cell-based immunotherapies for the treatment of cancer. The company specializes in tumor-infiltrating lymphocyte (TIL) therapies, which involve harnessing and enhancing a patient's immune cells to target and destroy cancer cells. Iovance’s research primarily targets solid tumors, aiming to offer new treatment options for patients with melanoma, cervical cancer, and other types of cancers. Its therapies are developed using advanced cell therapy technologies to address cancers that are resistant to traditional treatments. The company is headquartered in San Carlos, California, and its shares are listed on the NASDAQ.